Filtered By:
Drug: Abciximab
Procedure: Coronary Angioplasty

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
CONCLUSIONS: Mutations of glycoproteins Ia, Ib, IIb and IIIa did not influence platelet aggregation in response to tirofiban in patients with unstable angina and non-ST-segment elevation myocardial infarction. PMID: 26786608 [PubMed - as supplied by publisher]
Source: Sao Paulo Medical Journal - January 19, 2016 Category: Journals (General) Authors: Mansur AP, Roggerio A, Takada JY, Caribé PM, Avakian SD, Strunz CM Tags: Sao Paulo Med J Source Type: research

Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
CONCLUSIONS: The available trial evidence showed that, for individuals with acute ischaemic stroke, GP IIb-IIIa inhibitors are associated with a significant risk of intracranial haemorrhage with no evidence of any reduction in death or disability in survivors. These data do not support their routine use in clinical practice. The conclusion is driven by trials of Abciximab, which contributed 89% of the total number of study participants considered. PMID: 24609741 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 8, 2014 Category: Journals (General) Authors: Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I Tags: Cochrane Database Syst Rev Source Type: research